Top Stock Reports for Micron Technology, Roche & UnitedHealth

Wednesday, January 7, 2026

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Micron Technology, Inc. (MU), Roche Holding AG (RHHBY) and UnitedHealth Group Inc. (UNH). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Ahead of Wall Street

The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.

You can read today's AWS here >>> ADP Rebounds to +41K, JOLTS & ISM Services After the Open

Today's Featured Research Reports

Micron Technology’s shares have outperformed the Zacks Computer - Integrated Systems industry over the past six months (+186.2% vs. +61.2%). The company is benefiting from the rapidly expanding artificial intelligence (AI)-driven memory and storage markets. The positive impacts of inventory improvement across multiple end markets are driving top-line growth. 

The surging demand for HBM and robust DRAM pricing recovery will aid significant revenue and earnings growth in the coming quarters. Its solid financials, positive free cash flow and strong balance sheet provide the flexibility to invest in growth initiatives while enhancing shareholder value. 

Micron Technology’s long-term customer agreements and expanding AI partnerships reduce volatility and enhance revenue visibility. Nonetheless, rising operating costs and a massive increase in capital expenditure pose a downside risk to Micron’s near-term profitability.

(You can read the full research report on Micron Technology here >>>)

Shares of Roche have outperformed the Zacks Large Cap Pharmaceuticals industry over the past six months (+28% vs. +22%). The company’s performance in 2025 was good as high demand for key drugs has offset the decline in sales of legacy drugs. The stellar performances of multiple sclerosis drug Ocrevus and ophthalmology drug Vabysmo maintain momentum for Roche.

Growth in hemophilia treatment Hemlibra and breast cancer drug Phesgo also boosted the top line. Roche is also looking to diversify its portfolio through acquisitions and collaborations in the wake of declining sales from legacy drugs (Avastin, Herceptin, MabThera and Actemra) due to competition from biosimilars. 

The collaboration with Zealand Pharma for its obesity candidate should expand its pipeline. However, pipeline setbacks weigh on the stock. The performance of the Diagnostic division has been disappointing. Roche also made a late entry into the lucrative obesity space.

(You can read the full research report on Roche here >>>)

UnitedHealth’s shares have outperformed the Zacks Medical - HMOs industry over the past six months (+16.4% vs. +11.6%). The company has shown steady revenue growth, driven by Optum and UnitedHealthcare. Its strong market position and expansion initiatives, amid rising healthcare demand, support long-term growth. 

Optum remains a key driver via pharmacy services, tech integration and government solutions. Commercial membership also grew, aiding margins despite headwinds in government programs. Cash flow remains strong, with significant shareholder returns. 

However, rising medical costs have pushed MCR to 89.9% in the third quarter, while elevated debt and interest expenses strain financial flexibility. EPS guidance was sharply cut to at least $16, and leadership changes have added further uncertainty. Despite the share price fall over the past year, it is currently overvalued compared to the industry average. As such, the stock warrants a cautious stance.

(You can read the full research report on UnitedHealth here >>>)

Other noteworthy reports we are featuring today include Western Digital Corp. (WDC), Paychex, Inc. (PAYX) and DexCom, Inc. (DXCM).

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Today's Must Read

Rising AI Spending, Inventory Improvement Aid Micron (MU)

Vabysmo, Phesgo Fuel Roche (RHHBY), Decline in Legacy Drugs a Woe

UnitedHealth (UNH) Gains From Optum Growth and Commercial Members

Featured Reports

Cloud Computing Growth Aids Paychex (PAYX), Competition High
Per the Zacks analyst, Paychex benefits from the rising client adoption of cloud-based solutions. Fierce competition raises the difficulty in balancing growth and profitability.

Strong Product Portfolio Aids DexCom (DXCM) Fight Competition
Per the Zacks analyst, DexCom strong product portfolio targeting the large and growing diabetes market is helping the company fight intensifying competition with entry new competing products.

Contract Inflows and Solid Backlog Aid Leidos Holdings (LDOS)
According to the Zacks analyst, Leidos Holdings is benefiting from rising defense contract wins from the Pentagon and other U.S. allies. A strong $47.66B backlog supports revenue growth prospects.

Hasbro (HAS) Gains From Product Innovation Despite Tariff Risks
Per the Zacks analyst, Hasbro is gaining from high-margin Wizards and Licensing segments, cost discipline and new product innovation, though tariff uncertainty and higher expenses pose risks.

Organic Growth Support BOK Financial (BOKF) Amid High Expenses
Per the Zacks analyst, BOK Financial's organic strength is reflected by strong loan pipeline and rising deposit balances. However, elevated technological and compensation costs remain a concern.

Goodyear (GT) Buoyed by Cooper Tire Buyout Amid Huge Debt Pile
The acquisition of Cooper Tire has boosted Goodyear's leadership and expanded its foothold in other North American markets, but high leverage remains key concern, per the Zacks analyst.

TripAdvisor (TRIP) Benefits From Tripadvisor Core Strength
Per the Zacks analyst, growing momentum in TheFork and Tripadvisor experiences is aiding the company's Tripadvisor Core segment.

New Upgrades

Western Digital (WDC) Gains From Uptick in HDD Demand
Per the Zacks analyst, Western Digital is gaining from strong HDD demand, adoption of 26TB CMR and 32TB UltraSMR, and advances in ePMR and HAMR tech, which are expected to drive top-line growth ahead.

Onto Innovation (ONTO) Rides on Dragonfly Uptake Amid Tariff Woes
Per the Zacks analyst, Onto Innovation's top-line is gaining from higher demand for the Dragonfly platform. However, tariff pressure is likely to hit its margins in the near term.

Mercury General (MCY) Boasts Revenue Growth, Solid Balance Sheet
Per the Zacks analyst, Mercury General is set to grow on strong revenues driven by improved net investment income and rate increases. Moreover, its solid balance sheet provides financial flexibility.

New Downgrades

Novo Nordisk Experiences Global Slowdown Amid Intense Competition
Per the Zacks Analyst, NVO's growth prospects are hurting as Wegovy and Ozempic face slowing sales amid rising competition in the global obesity market.

Growing Debt Burden to Hurt Williams Companies (WMB)
The Zacks analyst believes that Williams' high debt-to-capital ratio raises financial risk, limiting flexibility for growth and downturn resilience.

Conagra (CAG) Battles Margin Headwinds as Cost Pressures Persist
Per the Zacks analyst, Conagra's margins remain under pressure. Gross margin contracted 292 bps in the second quarter and fiscal 2026 guidance points to operating margins well below historical levels.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research